These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11739028)

  • 1. Combination vaccines.
    Decker MD
    Prim Care; 2001 Dec; 28(4):739-61, vi. PubMed ID: 11739028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination vaccines.
    Edwards KM; Decker MD
    Infect Dis Clin North Am; 2001 Mar; 15(1):209-30. PubMed ID: 11301816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in the development, licensure, and use of combination vaccines.
    Postema AS; Myers MG; Breiman RF
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S261-6. PubMed ID: 11709757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.
    Lopalco PL; DeStefano F
    Vaccine; 2015 Mar; 33(13):1541-8. PubMed ID: 25444788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination vaccines.
    Chokephaibulkit K
    J Med Assoc Thai; 2002 Aug; 85 Suppl 2():S694-9. PubMed ID: 12403249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prelicensure evaluation of combination vaccines.
    Goldenthal KL; Falk LA; Ball L; Geber A
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S267-73. PubMed ID: 11709758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of combination vaccines: perception versus reality.
    Halsey NA
    Pediatr Infect Dis J; 2001 Nov; 20(11 Suppl):S40-4. PubMed ID: 11704723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and formulation issues of the combined vaccines.
    Tafreshi SH
    Expert Rev Vaccines; 2020 Oct; 19(10):949-958. PubMed ID: 33118470
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenges to vaccine safety.
    Marshall GS; Gellin BG
    Prim Care; 2001 Dec; 28(4):853-68, vii. PubMed ID: 11739033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention.
    Moro PL; Haber P; McNeil MM
    Expert Rev Vaccines; 2019 Oct; 18(10):1091-1101. PubMed ID: 31580725
    [No Abstract]   [Full Text] [Related]  

  • 13. Strategies for development of combination vaccines.
    Yeh SH; Ward JI
    Pediatr Infect Dis J; 2001 Nov; 20(11 Suppl):S5-9. PubMed ID: 11704717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges for licensure of new diphtheria, tetanus, acellular pertussis (DTaP) combination vaccines: point.
    Granoff DM
    Pediatr Infect Dis J; 1996 Dec; 15(12):1069-70. PubMed ID: 8970213
    [No Abstract]   [Full Text] [Related]  

  • 15. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer.
    Dolhain J; Janssens W; Mesaros N; Hanssens L; Fierens F
    Expert Rev Vaccines; 2018 Jun; 17(6):513-524. PubMed ID: 29920121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination vaccines consisting of acellular pertussis vaccines.
    Edwards KM; Decker MD
    Pediatr Infect Dis J; 1997 Apr; 16(4 Suppl):S97-102. PubMed ID: 9109164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Licensure, Approval, and Uptake of Vaccines in the United States.
    Pickering LK; Orenstein WA
    J Pediatric Infect Dis Soc; 2018 Dec; 7(suppl_2):S46-S48. PubMed ID: 30590618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges for licensure of new diphtheria, tetanus toxoid, acellular pertussis (DTaP) combination vaccines: counterpoint.
    Edwards KM; Decker MD
    Pediatr Infect Dis J; 1996 Dec; 15(12):1070-3. PubMed ID: 8970214
    [No Abstract]   [Full Text] [Related]  

  • 19. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
    Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM
    Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers.
    Lee AW; Jordanov E; Boisnard F; Marshall GS
    Expert Rev Vaccines; 2017 Feb; 16(2):85-92. PubMed ID: 27996332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.